Back to News
Market Impact: 0.3
Agios Q3 Mitapivat Revenue Surges More Than Fourfold; Sickle Cell FDA Decision Set For February 2027
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Agios Pharmaceuticals reported third-quarter 2026 results, with worldwide mitapivat revenue more than quadrupling year over year. The company attributed the growth to continued demand for AQVESME; the available article text provides no revenue amount or further financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
AGIO0.65
More News
- Truist cuts Agios Pharma stock price target on SCD concerns
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request